Medicis Pharmaceutical Corp. (MRX) Reports In-Line Q2 EPS of 64c
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $75.71 --0%
Revenue Growth %: +21.2%
Financial Fact:
Gross profit: 160.59M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +21.2%
Financial Fact:
Gross profit: 160.59M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q2 EPS of $0.64, in-line with the analyst estimate of $0.64. Revenue for the quarter came in at $190.8 million versus the consensus estimate of $188.79 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
- Thor Industries (THO) Misses Q4 EPS by 13c
- Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
